At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|November 11, 2022
Dr. J. Christopher Webster on the biggest challenge facing his urology practice
Author(s)Urology Times staff
Webster also shares his advice for young urologists entering community practice.
Advertisement
“[Finding staffing has] been a real challenge,” J. Christopher Webster, MD, FACS, says in this video. Webster is a urologist with Colorado Urology in Westminster. He was interviewed at the
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
4
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
5